RESULT OF PROLONGED COMBINED THERAPY PATIENTS WITH CHRONIC HEART FAILURE AND ARTERIAL HYPERTENSION WITH ANXIETY-DEPRESSIVE DISORDERS
Abstact. The article presents the results of original research of the Russian drug having neuroprotective, antidepressant, anxiolytic effects in the treatment of patients with ischemic heart diseases. It was noted that in recent years has increased the prevalence of anxiety and depressive disorders in cardiological patients with chronic heart failure and hypertension. A high social importance of disability in patients with chronic heart maintains an constant interest of clinicians to develop new techniques and methods of long-term treatment. Investigated the efficiency of the inclusion of the drug Pantogam active in the long-term (12-month) integrated cardiac therapy 98 patients with chronic heart failure and hypertension with anxiety and depressive disorders. Evaluation of result took place not only with the help of instrumental methods, but also with the use of specialized standardized questionnaires. The main effect of the drug is due to the increasing resistance the brain to hypoxia, stimulating anabolic processes in neurons, reduction of excitability of the motoneurons. It has been shown that treatment with Pantogam active is accompanied by a significant reduction of anxiety and depressive disorders, improving autonomic regulation of the heart function, the trend towards a stabilization of blood pressure, increased exercise tolerance, reduced rates of unplanned hospitalization due to worsening of symptoms of chronic heart failure, unstable arterial hypertension or coronary heart disease, as well as a marked improvement in the quality of life.